RNS Number : 3757E
Valereum PLC
09 April 2025

This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

09/04/2025

Valereum Plc

("Valereum", "VLRM" or the "Company")

DMC £19m Subscription - Expected Completion
£1m Conditional Fundraise Terminated

Valereum Plc (AQSE: VLRM) would like to inform the markets that the previously announced £19 million strategic deal with DMC is nearing completion and all documents have been signed and are held in escrow by the Company's legal advisers. On receipt of funds, we will update the markets accordingly.

The previously proposed additional £1 million subscription by a UK institutional investor will no longer proceed.

For more information, and the chance to have your questions directly answered by the management team, please head to our interactive investor hub via: Investor Hub. Here you will find all company news and additional content to further explain Valereum's strategy and products.

For further information, please contact:

Valereum Plc Peter Sekhon, Investor Relation Director Engage with the company directly	Tel: +44 7938 767319 Investor Hub
Stanford Capital Partners Bob Pountney/ Patrick Claridge	Tel: +44 023 3650 3650
AQSE Corporate Adviser **First Sentinel Corporate Finance** Brian Stockbridge / Gabrielle Cordeiro	Tel: +44 20 3855 5551

The Directors of the Company accept responsibility for the contents of this announcement.

For more information, please visit the Company's website at www.vlrm.com or to engage with the Valereum management team directly by asking questions, watching video summaries and seeing what other shareholders have to say.

Navigate to our Interactive Investor hub here: Sign Up

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXILMITMTAMBTA